Nektar Therapeutics 2017 Cowen Healthcare Conference

Nektar Therapeutics presented at Cowen & Company's 37th Annual Healthcare Conference in March 2017, highlighting its biopharmaceutical pipeline including ONZEALD for metastatic breast cancer, NKTR-181 abuse-deterrent opioid, and NKTR-214 IL-15 agonist. The company outlined integrated R&D capabilities across facilities in San Francisco, Huntsville, and Hyderabad, with projected revenue of $375-450M annually by 2021 from its partnered portfolio.